GetTopicDetailResponse(id=8dd7128033e5, topicName=limertinib, introduction=, content=肺癌 limertinib, image=null, comments=0, allHits=229, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Mon Jun 23 13:38:19 CST 2025, time=2025-06-23, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=505793, tagList=[TagDto(tagId=505793, tagName=limertinib)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2270526, encodeId=d84122e0526b3, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=8dd7128033e5' target=_blank style='color:#2F92EE;'>#limertinib#</a>, objectTitle=Lancet Respir Med：三代 EGFR-TKI 藥物 limertinib 一線治療 NSCLC，中位 PFS 達(dá) 20.7 個月！, objectType=article, longId=883925, objectId=4a6188392510, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241230/1735530667211_8538692.png, objectUrl=/article/show_article.do?id=4a6188392510, replyNumber=0, likeNumber=30, createdTime=2025-06-23, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4a6188392510, moduleTitle=Lancet Respir Med：三代 EGFR-TKI 藥物 limertinib 一線治療 NSCLC，中位 PFS 達(dá) 20.7 個月！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4a6188392510)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-06-23發(fā)表于上海
